Connect with us

Politics

DC Council Approves Bill That Will Help Psychedelics Decriminalization Initiative Qualify For Ballot Despite Coronavirus

Published

on

Members of the Washington, D.C. Council unanimously approved a bill on Tuesday that would help activists behind a psychedelics decriminalization measure qualify for the November ballot despite complications resulting from the coronavirus pandemic. Separately, the campaign shared with Marijuana Moment the details of a new signature gathering strategy it plans to launch when its petitions are officially approved by the District this week.

Councilmember Charles Allen (D) proposed the key electoral provisions of the broader COVID-19 emergency legislation, which would allow ballot initiative campaigns to electronically distribute petition sheets to their signature gatherers and let those petitioners return their collections to organizers in digital form. Voters would still have to physically sign printed sheets, but those could then be scanned and sent back to campaign headquarters.

The legislation would also, for the first time, enable ballot petitioners to sign sheets that they themselves are circulating. Currently, circulators are not allowed to sign their own petition and must use one controlled by a separate person—a policy that is contributing to the difficulty advocates are facing during a time of social distancing and stay-at-home orders.

Another change to the signature gathering process included in the proposal would eliminate a requirement that petitions be printed on legal-sized paper, rather than on the standard size that most people have in their home printers.

Together, the reforms will make it much easier for voters to print petitions, sign them and return them to the Decriminalize Nature D.C. campaign, which is seeking to deprioritize enforcement of laws against a wide range of entheogenic substances such as psilocybin mushrooms and ayahuasca.

“Though it is uncertain how long the District’s state of emergency will last, it is clear that the need for social distancing will continue in some form throughout the summer, thus limiting the ability of candidates and initiative proposers to gather large numbers of signatures and obtain ballot access,” Allen, who chairs the Council’s Committee on the Judiciary and Public Safety, wrote in a memo to Council Chairman Phil Mendelson (D). “These changes will allow eligible District residents to download petition sheets from campaigns at home, print them out, circulate them for physical signatures within their small social networks or families, and return them electronically to the campaigns.”

“The legislation recognizes that signatures protect democracy by serving as indicators of viability and preventing confusing ballots, while accounting for the unprecedented changes required by the public health emergency.”

Separately, on Wednesday, the D.C. Board of Elections is scheduled to both approve ballot petitions for the decriminalization measure and enact on their own a policy change allowing signature gatherers to sign the sheets they’re circulating.

Decriminalize Nature D.C. previously implored local officials to allow them to gather signatures purely electronically to minimize the spread of the virus while also ensuring that they have a fighting chance of qualifying. Neither the mayor or Council has not acted on that request, however, leading the campaign to recalibrate and develop alternative strategies.

With the self-signature problem solved through the proposed legislation, the group told Marijuana Moment it is prepared to proceed with a strategic experiment to build up support ahead of the July 6 deadline to submit about 25,000 valid signatures from registered voters.

The test will initially involve mailing out 10,000 petitions for the decriminalization initiative, along with educational materials.

The mailers will be evenly distributed to four classes of residents: 1) consistent voters who signed the ballot petition for a 2014 marijuana legalization initiative, 2) consistent voters who didn’t sign the legalization petition, 3) occasional voters who backed the cannabis petition and 4) a random selection of residents pulled from the voter roll.

“Initiative 81 would make a small change: shifting enforcement of laws against natural plant medicines to be among the lowest law enforcement priorities,” chief petitioner Melissa Lavasani said in the campaign material being mailed to voters. “This change would help me and thousands of other D.C. residents suffering from anxiety, PTSD, addiction, or depression who currently fear arrest or prosecution for pursuing healing through natural, entheogenic substances.”

“Signing and mailing back this petition is the first step towards ensuring safe and equitable access for all people to entheogenic plants and fungi,” the mailer states.

The campaign will assess the response rates from these respective groups and use that to inform their next step, which would be sending significantly more petitions out to voters. Contributions from the activist soap company Dr. Bronner’s, which is backing a number of drug policy campaigns across the country, will help fund the effort.

This new development for the D.C. campaign comes at a time when drug reform campaigns are either shuttering or temporarily suspending activities amid the pandemic.

California activists had hoped to get a measure to legalize psilocybin on the state’s November ballot, but the campaign stalled out amid the coronavirus pandemic.

Organizers in Oregon are holding out hope that a measure to legalize psilocybin for therapeutic purposes will make the ballot. The campaign already collected enough raw signatures to qualify, though they’ve yet to be validated.

Also in Oregon, a separate proposed ballot measure would decriminalize possession of all illicit drugs and use existing marijuana tax revenue to fund expanded treatment services. Activists in nearby Washington State are also working on a similar drug decriminalization and treatment measure.

Marijuana-specific reform campaigns have also felt the sting of the pandemic.

A Montana cannabis legalization campaign that sued the state to allow digital signature collection had their case dismissed last week, but organizers say they may file an appeal and will be pushing ahead despite the legal setback.

In Arizona, the organizers of a legalization effort are petitioning the state Supreme Court to instruct the secretary of state to allow people to sign cannabis petitions digitally using an existing electronic system that is currently reserved for individual candidates seeking public office.

A California campaign seeking to amend the state’s cannabis law also asked for a digital petitioning option.

A campaign to legalize cannabis in Missouri officially gave up its effort for 2020 last month due to signature collection being virtually impossible in the face of social distancing measures.

Idaho medical cannabis activists announced that they are suspending their ballot campaign, though they are still “focusing on distributing petitions through online download at IdahoCann.co and encouraging every volunteer who has downloaded a petition to get them turned in to their county clerk’s office by mail, regardless of how many signatures they have collected.”

North Dakota advocates said that they are suspending their campaign to put marijuana legalization on the November ballot due to the coronavirus outbreak.

Activists behind a campaign to legalize medical cannabis in Nebraska are holding out hope that they will qualify and recently unveiled a new strategy amid the pandemic.

In New York, Gov. Andrew Cuomo (D) conceded last month that the 2020 legalization push is “effectively over” in the legislature. Coronavirus shifted priorities, and comprehensive cannabis reform seems to have proved too complicated an issue in the short-term.

See Decriminalize Nature D.C.’s mailer to voters below:



DNDCpahPRINTfistversion01 (Text)

New York Lawmaker Files Bill To Decriminalize Psychedelic Mushrooms

Photo elements courtesy of carlosemmaskype and Apollo.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Politics

Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer

Published

on

“These aren’t just numbers and there are families attached.”

By Ned Oliver, Virginia Mercury

Virginia has sealed records documenting more than 64,000 misdemeanor marijuana distribution charges since the state legalized the drug in July.

The figure came out Thursday during a meeting of the legislature’s Cannabis Oversight Commission.

Officials said the records were scrubbed from the state’s criminal record database, which is used by employers like school boards, state agencies and local governments to screen employees.

The state had already sealed 333,000 records detailing charges of simple possession last year after the state reduced the offense to a civil infraction on par with a traffic offense, said Shawn G. Talmadge, the Deputy Secretary of Public Safety and Homeland Security.

Lawmakers directed the state to expand that effort when they voted to broadly legalize recreational use of marijuana earlier this year.

The legislature also agreed to a broader expungement reform that will automatically seal other misdemeanor charges, including underage possession of alcohol, use of a fake ID, petit larceny, trespassing and disorderly conduct. Talmadge said those charges will remain in the system until the state finishes updating the software it uses to track criminal records.

“As of right now, the process is proceeding,” he said.

Members of the oversight commission also heard from two advocates who urged them to move fast to address people currently imprisoned for marijuana offenses—a category of people the legalization legislation passed this year did not address.

Chelsea Higgs Wise, the leader of the advocacy group Marijuana Justice, and Gracie Burger, with the Last Prisoner Project, said Department of Corrections data suggests there are currently 10 people being held solely on serious marijuana charges.

They said it remains unknown how many more are being held because of marijuana related probation violations.

“These aren’t just numbers and there are families attached,” Burger said.

This story was first published by Virginia Mercury,

Nevada Sold More Than $1 Billion In Marijuana In One Year, Officials Report

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone

Published

on

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year.

In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.

DEA had already massively upped its proposed 2021 quota for cannabis and psilocybin last month, but now it’s calling for significantly larger quantities of research-grade marijuana and a broader array of psychedelics to be manufactured in 2022.

It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT. What especially stands out in the notice is MDMA. The agency is proposing an enormous 6,300 percent boost in the production of that drug—from just 50 grams in 2021 to 3,200 grams in the coming year—as research into its therapeutic potential continues to expand.

LSD would see a 1,150 percent increase, up to 500 grams of the potent psychedelic.

Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 million grams in 2022 from the 2 million grams last year.

Here’s a visualization of the proposed quota increase from 2021 to 2022 for marijuana and cannabis extracts:

For all other THC, psilocybin, psilocyn and MDMA:

And for other psychedelic substances like LSD, mescaline and DMT:

DEA said in the Federal Register notice that it has been receiving and approving additional applications to “grow, synthesize, extract, and manufacture dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes” to achieve these ambitious quotas.

“DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021,” the agency said, adding that it working “diligently” to process and approve marijuana manufacturers applications in particular, as there’s currently only one farm at the University of Mississippi that’s permitted to cultivate the plant for research.

“Based on the increase in research and clinical trial applications, DEA has proposed increases in 3,4- Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, Lysergic acid diethylamide (LSD), Marihuana, Marihuana Extract, Mescaline, Psilocybin, Psilocyn, and All Other Tetrahydrocannabinols to support manufacturing activities related to the increased level of research and clinical trials with these schedule I controlled substances.”

Here are the exact numbers for the proposed 2021 and 2022 quotas:

Substance 2021
2022 proposed
Marijuana 2,000,000 3,200,000
Marijuana extract 500,000 1,000,000
All other tetrahydrocannabinol 1,000 2,000
Psilocybin 1,500 3,000
Psilocyn 1,000 2,000
MDMA 50 3,200
LSD 40 500
Mescaline 25 100
DMT 50 250
5-MeO-DMT 35 550
MDA 55 200

A 30-day public comment period will be open after the notice is formally published on Monday.

It’s difficult to overstate just how significant the proposed 2022 increases are, but it’s certainly true that scientific and public interest in marijuana and psychedelics has rapidly increased, with early clinical trials signaling that such substances show significant therapeutic potential.

National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.

Advocates and experts remain frustrated that these plants and fungi remain in the strictest federal drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.

A federal appeals court in August dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.

Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.

Singer Melissa Etheridge And Activist Van Jones Promote Psychedelics Reform As Movement Grows

Image element courtesy of Kristie Gianopulos.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

Supreme Court Won’t Hear Case On Legalizing Safe Drug Consumption Sites, But Activists Are Undeterred

Published

on

The U.S. Supreme Court (SCOTUS) has rejected a request to hear a case on the legality of establishing safe injection sites where people can use illicit drugs in a medically supervised environment.

The justices announced on Tuesday that they decided against taking up the case raised by the nonprofit Safehouse, despite the pleas of attorneys general from 10 states and D.C. who recently filed amici briefs urging the court’s involvement.

Representatives from 14 cities and counties, as well as the mayor of Philadelphia, which is at the center of the current case, also filed briefs in support of the case in recent days.

Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration. It filed a petition with the nation’s highest court in August to hear the case.

But while the Supreme Court declined to take action—and the Biden administration passed up its voluntary opportunity to weigh in at this stage, which may well have influenced the justices’ decision—activists say the battle will continue at a lower federal court level, where the administration will have to file briefs revealing its position on the issue.

“We were disappointed that the government chose not to respond to our petition,” Safehouse Vice President Ronda Goldfein told Filter. “They said, ‘We’re going to waive our right to respond,’ [and] the Supreme Court declined to review our case. Ordinarily that sounds like the end of the road—but in our case we are still pursuing our claims in a different venue.”

That venue will be the the federal district court in Philadelphia, where activists plan to submit multiple arguments related to religious freedom and interstate commerce protections. The Biden administration will be compelled to file a response in that court by November 5.

“If they don’t respond, they lose,” Goldfein said.

A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—previously filed a brief urging the Supreme Court to take up Safehouse’s safe injection case.

Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.

If the Supreme Court were to have taken the case and rule in favor of Safehouse, it could have emboldened advocates and lawmakers across the country to pursue the harm reduction policy.

The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.

Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.

A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.

Florida Democratic Candidates For Governor Fight Over Who Supports Marijuana Reform The Most

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment